BIOFRONTERA AG/ADR (BFRA) PT Raised to $24.00 at Lake Street Capital

BIOFRONTERA AG/ADR (NASDAQ:BFRA) had its price objective boosted by Lake Street Capital from $19.00 to $24.00 in a research note published on Tuesday morning, The Fly reports. The brokerage currently has a buy rating on the stock.

Separately, Benchmark reaffirmed a buy rating on shares of BIOFRONTERA AG/ADR in a research report on Tuesday, March 26th.

NASDAQ:BFRA opened at $14.38 on Tuesday. The stock has a market cap of $318.13 million, a PE ratio of -30.60 and a beta of 1.09. BIOFRONTERA AG/ADR has a 1 year low of $11.04 and a 1 year high of $16.06. The company has a quick ratio of 5.58, a current ratio of 6.28 and a debt-to-equity ratio of 1.02.

BIOFRONTERA AG/ADR (NASDAQ:BFRA) last released its quarterly earnings data on Monday, April 29th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.01). The business had revenue of $7.48 million for the quarter. BIOFRONTERA AG/ADR had a negative return on equity of 98.81% and a negative net margin of 71.55%.

BIOFRONTERA AG/ADR Company Profile

Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of actinic keratosis.

Further Reading: What is a Fiduciary?

The Fly

Receive News & Ratings for BIOFRONTERA AG/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOFRONTERA AG/ADR and related companies with MarketBeat.com's FREE daily email newsletter.